Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MNMD

Mind Medicine Inc

Sep 27 • 04:00PM ET

5.85

Dollar change -0.04
Percentage change -0.68	%

Healthcare • Biotechnology • USA • NASD

Held by: IWM VXF IWO SCHA VTWO XPH VHT IHE IWC PSIL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.26	Insider Own	3.19%	Shs Outstand	41.10M	Perf Week	-2.01%
Market Cap	164.74M	Forward P/E	-	EPS next Y	-1.36	Insider Trans	-7.17%	Shs Float	27.27M	Perf Month	-0.26%
Income	-102.04M	PEG	-	EPS next Q	-0.28	Inst Own	144.16%	Short Float	34.64%	Perf Quarter	-18.86%
Sales	0.00M	P/S	-	EPS this Y	38.36%	Inst Trans	-	Short Ratio	8.64	Perf Half Y	-37.77%
Book/sh	2.80	P/B	2.09	EPS next Y	9.35%	ROA	-49.75%	Short Interest	9.45M	Perf Year	66.19%
Cash/sh	8.63	P/C	0.68	EPS next 5Y	-	ROE	-66.26%	52W Range	2.41 - 12.22	Perf YTD	59.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	2.29%	ROI	-45.09%	52W High	-52.13%	Beta	1.62
Dividend TTM	-	Quick Ratio	5.92	Sales past 5Y	0.00%	Gross Margin	-	52W Low	142.74%	ATR (14)	0.35
Dividend Ex-Date	-	Current Ratio	5.92	EPS Y/Y TTM	-7.77%	Oper. Margin	0.00%	RSI (14)	41.76	Volatility	3.43% 5.60%
Employees	57	Debt/Eq	0.12	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.10	Target Price	26.00
Option/Short	Yes / Yes	LT Debt/Eq	0.12	EPS Q/Q	89.22%	Payout	-	Rel Volume	0.40	Prev Close	5.89
Sales Surprise	-	EPS Surprise	75.54%	Sales Q/Q	-	Earnings	Aug 13 BMO	Avg Volume	1.09M	Price	5.85
SMA20	-3.40%	SMA50	-15.13%	SMA200	-15.31%	Trades		Volume	432,852	Change	-0.68%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-24-24	Initiated	ROTH MKM	Buy	$36
May-29-24	Initiated	Robert W. Baird	Outperform	$27
Apr-15-24	Initiated	Leerink Partners	Outperform	$20
Dec-05-23	Initiated	Canaccord Genuity	Buy	$9
Dec-09-22	Resumed	ROTH Capital	Buy	$25
Nov-16-22	Initiated	RBC Capital Mkts	Outperform	$5
Aug-26-22	Initiated	Oppenheimer	Outperform	$3.50
Aug-10-22	Initiated	Cantor Fitzgerald	Overweight	$3
May-04-22	Initiated	ROTH Capital	Buy	$7
Jun-28-21	Initiated	Maxim Group	Buy	$6

Sep-09-24 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Sep-04-24 07:00AM	MindMed to Participate in September Investor Conferences (Business Wire) +5.86%
Aug-13-24 07:00AM	MindMed Reports Second Quarter 2024 Financial Results and Business Updates (Business Wire)
Aug-12-24 09:02PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Aug-09-24 08:44AM	Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering (Business Wire) -10.03%
06:00AM	Loading…
06:00AM	Mind Medicine (MindMed) Inc. Announces Proposed Public Offering (Business Wire)
Aug-06-24 04:01PM	MindMed to Present at Canaccord Genuitys 44th Annual Growth Conference (Business Wire)
07:00AM	MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update (Business Wire)
Jul-29-24 07:00AM	MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer (Business Wire)
Jul-17-24 07:00AM	MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT) (Business Wire)
Jul-06-24 07:21AM	3 Psychedelic Stocks to Ride to the Moon and Beyond (InvestorPlace)
Jul-04-24 02:13PM	FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals (InvestorPlace)
Jun-28-24 07:00AM	MindMed to be Included in Russell 2000 and Russell 3000 Indexes (Business Wire)
Jun-21-24 07:00AM	MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (Business Wire)
Jun-20-24 07:00AM	MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD) (Business Wire)
12:31PM	Loading…
Jun-18-24 12:31PM	Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024 (InvestorPlace)
Jun-14-24 09:40AM	Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year? (Zacks)
Jun-05-24 11:42AM	Psychedelic Drug Stocks Plummet On FDA Advisers' Doubts About Ecstasy Candidate (The Wall Street Journal) -10.06%
May-29-24 09:40AM	Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year? (Zacks) +6.64%
May-28-24 07:00AM	MindMed to Participate in June Conferences (Business Wire)
May-23-24 03:41PM	The Time Traveler's Portfolio: 3 Stocks to Buy Now for Massive Returns by 2034 (InvestorPlace) -5.36%
May-18-24 09:32AM	Jim Cramer's Latest Stock Picks in May 2024 (Insider Monkey)
May-10-24 11:00AM	Top Russell 2000 Picks: 3 Small-Cap Stocks to Scoop Up This May (InvestorPlace)
May-09-24 04:01PM	MindMed to Participate at May Investor Conferences (Business Wire) -5.10%
08:00AM	New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US (Business Wire)
06:49AM	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine (InvestorPlace)
May-08-24 09:00PM	MNMD Stock Earnings: Mind Medicine Misses EPS for Q1 2024 (InvestorPlace)
04:01PM	MindMed Reports First Quarter 2024 Financial Results and Business Updates (Business Wire)
May-04-24 08:00AM	MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York (Business Wire)
May-02-24 07:00AM	MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update (Business Wire)
07:00AM	Loading…
Apr-25-24 07:00AM	MindMed to Present at Upcoming May Medical Conferences (Business Wire)
Apr-08-24 06:59AM	MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why (Zacks)
Apr-02-24 07:00AM	MindMed to Present at Upcoming April Medical Conferences (Business Wire)
Apr-01-24 05:00PM	MindMed Announces Voluntary Delisting from Cboe Canada (Business Wire)
Mar-19-24 08:00AM	The Next Great Biotech Boom Has Arrived (PR Newswire)
Mar-11-24 07:00AM	MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference (Business Wire) -14.02%
Mar-10-24 11:10AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-08-24 10:46AM	MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag (Zacks) +7.78%
07:00AM	Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder (PR Newswire)
Mar-07-24 07:13AM	Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement (Business Wire) +51.52%
06:00AM	MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder (Business Wire)
Mar-01-24 09:00AM	MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120 (Business Wire) +9.01%
Feb-28-24 07:05AM	MindMed Reports 2023 Financial Results and Business Updates (Business Wire)
Feb-22-24 07:00AM	MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update (Business Wire)
Feb-07-24 07:00AM	MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference (Business Wire)
Jan-24-24 09:00AM	How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition (PR Newswire) -5.59%
Jan-08-24 12:27PM	Canadian Investment Regulatory Organization Trading Halt - MMED.WR (PR Newswire) +7.33%
07:45AM	MindMed Announces Business Update and Anticipated Milestones for 2024 (Business Wire)
Dec-17-23 05:49PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Dec-14-23 07:30AM	MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (Business Wire) +11.46%
Dec-11-23 12:19PM	Canadian Investment Regulatory Organization Trading Halt - MMED.WA (PR Newswire)
Nov-02-23 04:01PM	MindMed Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire) +8.43% +14.44%
Oct-30-23 12:11PM	Canadian Investment Regulatory Organization Trading Halt - MMED.WS (PR Newswire)
Oct-26-23 07:30AM	MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update (Business Wire)
Oct-24-23 07:30AM	MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) (Business Wire)
Oct-03-23 07:30AM	MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress (Business Wire)
Sep-14-23 07:30AM	MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit (Business Wire) +6.42%
Sep-12-23 07:30AM	MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD) (Business Wire)
Aug-28-23 07:30AM	MindMed to Participate at September Investor Conferences (Business Wire)
Aug-14-23 07:30AM	MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures (Business Wire)
Aug-03-23 04:01PM	MindMed Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire) -7.64%
07:30AM	MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120 (Business Wire)
Jul-31-23 08:30AM	MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business Update (Business Wire) +13.07%
Jun-22-23 08:42AM	FCM Received Significant Support from Shareholders, Disappointed that Passive Investors Saw Fit to Give Incumbent Directors Another Chance to Disappoint (GlobeNewswire)
08:30AM	MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference (Business Wire)
Jun-21-23 12:08PM	MindMed Announces Election of All Six Company Nominees at Annual Meeting (Business Wire)
Jun-20-23 08:30AM	MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor Day (Business Wire)
Jun-15-23 04:23PM	FCM Denounces MindMeds Manipulation of Corporate Machinery to Protect Incumbent Board of Directors (GlobeNewswire)
10:45AM	MindMed Adjourns Annual General Meeting of Shareholders (Business Wire)
Jun-09-23 09:00AM	MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th Deadline (Business Wire)
Jun-08-23 11:30AM	Leading Proxy Advisory Firm Glass Lewis Recommends MindMed Shareholders Vote FOR All Six Company Nominees (Business Wire)
Jun-07-23 08:07AM	FCM Plans for MM-120 (LSD) FDA Approval in 2026 And Extends Share Lockup Until June 15, 2026 (GlobeNewswire)
08:00AM	MindMed to Host Investor Day June 2023 (Business Wire)
Jun-05-23 08:00AM	Leading Proxy Advisory Firm ISS Recommends MindMed Shareholders Vote FOR All Six Company Nominees (Business Wire)
07:00AM	Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120 (PR Newswire)
Jun-02-23 04:17PM	FCM Predicts Psychedelic Revolution In 2024: Urges Shareholders to Position MindMed for Success with a Reconstituted Board (GlobeNewswire)
Jun-01-23 07:00AM	MindMed to Participate at Upcoming Investor Conferences (Business Wire)
May-30-23 04:17PM	FCM Pledges to Lock Up its MindMed Shares Until June 2025 to Demonstrate its Alignment with Fellow Shareholders and Confidence in its Plan to Restore MindMed (GlobeNewswire)
May-25-23 04:57PM	FCM Concerned MindMeds Mismanagement Threatens Mental Health for Millions (GlobeNewswire) +5.52%
04:00PM	MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders (Business Wire)
08:00AM	MindMed Publishes Report by Leading FDA Experts Validating MindMeds MM-120 Drug Development Strategy (Business Wire)
May-24-23 07:00AM	MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting (Business Wire)
May-17-23 04:01PM	MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD) (Business Wire)
May-15-23 08:24AM	FCM Director Nominees Will Put MindMed Drug Development Process Back on Track (GlobeNewswire)
May-05-23 08:08AM	FCM Releases Letter to Fellow MindMed Shareholders Highlighting Board and Managements Track Record of Shareholder Value Destruction (GlobeNewswire) -5.80%
May-04-23 04:02PM	MindMed Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-02-23 08:00AM	MindMed Sends Letter to Shareholders Highlighting Companys Positive Momentum and Value-Enhancing Strategy (Business Wire)
May-01-23 04:01PM	MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update (Business Wire)
Apr-26-23 07:00AM	MindMed to Participate in May Investor Conferences (Business Wire)
Apr-21-23 08:22AM	FCM Nominates Exceptional Director Candidates to Restore MindMeds Value (GlobeNewswire)
Apr-18-23 04:15PM	MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting (Business Wire)
Apr-14-23 07:00AM	MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD) (Business Wire)
Apr-13-23 07:00AM	MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary (Business Wire)
Mar-09-23 04:02PM	MindMed Reports Full Year 2022 Financial Results and Business Highlights (Business Wire) -5.35%
Feb-28-23 07:30AM	MindMed to Participate in March Investor Conferences (Business Wire)
Feb-16-23 03:45PM	Nasdaq Gets a Healthy Dose of Psychedelics With Lucy Scientific (Exec Edge)
Jan-17-23 05:00AM	Trippy Trading: Top Psychedelic Stocks For 2023 (News Direct) +9.48%
Jan-09-23 07:30AM	MindMed Provides Corporate Update and 2023 Outlook (PR Newswire)
Dec-01-22 07:30AM	MindMed to Participate in the Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health Conference (PR Newswire) +5.29%
Nov-14-22 08:08AM	Activist Investor Informs MindMed of Financial Misstatements, Questions Internal Controls (GlobeNewswire)

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sullivan, Mark	Officer	Sep 25 '24	Proposed Sale	5.98	4,430	26,487		Sep 25 08:31 PM
Liao Carrie	Chief Accounting Officer	Sep 25 '24	Sale	5.98	2,352	14,065	99,543	Sep 25 08:30 PM
Barrow Robert	Chief Executive Officer	Sep 25 '24	Sale	5.98	19,771	118,231	545,772	Sep 25 08:29 PM
Karlin, Dan	Officer	Sep 25 '24	Proposed Sale	5.98	6,871	41,081		Sep 25 08:29 PM
Karlin Dan	Chief Medical Officer	Sep 25 '24	Sale	5.98	6,871	41,089	344,656	Sep 25 08:29 PM
Sullivan Mark	Chief Legal Officer	Sep 25 '24	Sale	5.98	4,430	26,491	177,716	Sep 25 08:28 PM
Barrow, Robert	Officer, Director	Sep 25 '24	Proposed Sale	5.98	19,771	118,210		Sep 25 08:27 PM
GRYSKA DAVID W	Director	Aug 23 '24	Buy	5.98	3,500	20,930	17,351	Aug 26 07:00 PM
Halperin Wernli Miri	Executive President	Aug 21 '24	Option Exercise	3.70	50,000	185,000	235,000	Aug 22 04:30 PM
Barrow Robert	Chief Executive Officer	Aug 19 '24	Buy	6.31	500	3,155	565,043	Aug 20 09:14 PM
Barrow Robert	Chief Executive Officer	Aug 20 '24	Buy	6.12	500	3,060	565,543	Aug 20 09:14 PM
Karlin Dan	Chief Medical Officer	Jun 25 '24	Sale	7.22	6,925	49,998	351,527	Jun 25 07:00 PM
Sullivan Mark	Chief Legal Officer	Jun 25 '24	Sale	7.22	17,854	128,906	182,146	Jun 25 07:00 PM
Barrow Robert	Chief Executive Officer	Jun 25 '24	Sale	7.22	15,659	113,058	564,543	Jun 25 07:00 PM
Karlin Dan	Chief Medical Officer	Mar 25 '24	Sale	9.50	6,578	62,491	358,452	Mar 26 05:15 PM
Barrow Robert	Chief Executive Officer	Mar 25 '24	Sale	9.50	16,519	156,930	580,202	Mar 26 05:15 PM
Karlin Dan	Chief Medical Officer	Dec 26 '23	Sale	3.63	6,774	24,590	365,030	Dec 26 04:59 PM
Barrow Robert	Chief Executive Officer	Dec 26 '23	Sale	3.63	13,237	48,050	596,721	Dec 26 04:50 PM
Greenway Schond L.	Chief Financial Officer	Dec 26 '23	Sale	3.63	5,652	20,517	216,617	Dec 26 04:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MNMD

Mind Medicine Inc

Upgrade your FINVIZ experience